The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | Risk stratification of MGUS
Vincent Rajkumar
• 16 May 2019
Monoclonal gammopathy of unknown significance effects 3-4% of the general population, 50 years of age and above. Vincent Rajkumar, MD from the Mayo Clinic, Rochester, MN, presents methods to stratify the risk of disease progression to multiple myeloma. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
